GILD · 10-Q · 2026Q3 · Full report
Liver Disease Sales Growth
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 26 · Surprise 32 · No source text
Liver Disease product sales increased 13% to $927 million in the third quarter and 8% to $2.6 billion for the first nine months of 2026. Higher demand for Livdelzi drove growth in both periods, with nine-month growth also supported by HBV products and Hepcludex. Lower demand for HCV products partially offset growth, although higher realized prices for HCV and HBV products contributed in the third quarter.
Key facts
- Gilead’s liver disease product sales increased 13% to $927 million in Q3 2026, primarily due to higher Livdelzi demand and higher realized prices for HCV and HBV products, partly offset by lower HCV demand. source
- Gilead’s liver disease product sales increased 8% to $2.6 billion for the nine months ended September 30, 2026, primarily from higher demand for Livdelzi, HBV products and Hepcludex, partly offset by lower HCV sales. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +1.3% | Gilead’s liver disease product sales increased 13% to $927 million in Q3 2026, primarily due to higher Livdelzi demand and higher realized… |